NCT06526013 Cholesterol Self-testing in Patients Post Acute Coronary Syndrome
| NCT ID | NCT06526013 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Leipzig |
| Condition | Acute Coronary Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-06-01 |
| Primary Completion | 2025-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2024-06-01 with a primary completion date of 2025-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The pharmacological reduction of LDL-C lowers cardiovascular risk and is therefore a priority in cardiovascular secondary prevention. The achievement of LDL-C target levels in Germany, Europe, and worldwide is inadequate, despite a wide array of lipid-lowering medications. Only a small proportion of post-myocardial infarction patients reach their LDL-C target range within a year. There is a significant need for new strategies to improve LDL-C target achievement and thereby reduce the occurrence of secondary cardiovascular events. The aim of the study is to establish a basis for improving prevention by achieving the target LDL level effectively and quickly in patients with high and very high cardiovascular risk profiles.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Patients with acute coronary syndrome in the last 6 months and not having reached the LDL target value * Signed informed consent Exclusion Criteria: * Persons unable to understand the study * Persons unable or unwilling to perform self-measurements * Persons unable or unwilling to undergo additional cholesterol-lowering therapy to reach the LDL target * Pre-menopausal women without contraception * Use of experimental drugs or investigational products within 30 days prior to screening * Employees or contractors of the institution conducting the study or family members of the Principal Investigator, Co-Investigator, or financial supporter
Contact & Investigator
Ulrich Laufs, Professor
STUDY CHAIR
University Clinik, Clinic for Cardiology Leipzig
Frequently Asked Questions
Who can join the NCT06526013 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Coronary Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06526013 currently recruiting?
Yes, NCT06526013 is actively recruiting participants. Contact the research team at irina.mueller-kozarez@medizin.uni-leipzig.de for enrollment information.
Where is the NCT06526013 trial being conducted?
This trial is being conducted at Leipzig, Germany.
Who is sponsoring the NCT06526013 clinical trial?
NCT06526013 is sponsored by University of Leipzig. The principal investigator is Ulrich Laufs, Professor at University Clinik, Clinic for Cardiology Leipzig. The trial plans to enroll 200 participants.